Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Atrioventricular block second degree? 14 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Atrioventricular block second degree have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

14
Reports of Atrioventricular block second degree with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
2
Deaths
13
Hospitalizations

How Dangerous Is Atrioventricular block second degree From PEMBROLIZUMAB?

Of the 14 reports, 2 (14.3%) resulted in death, 13 (92.9%) required hospitalization.

Is Atrioventricular block second degree Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 14 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Atrioventricular block second degree?

FINGOLIMOD (167) DILTIAZEM (76) BISOPROLOL (73) METOPROLOL (67) OMEPRAZOLE (64) AMLODIPINE (58) ASPIRIN (55) LACOSAMIDE (55) AMIODARONE (49) FLUOXETINE (44)

Which PEMBROLIZUMAB Alternatives Have Lower Atrioventricular block second degree Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Atrioventricular block second degree Reports All Drugs Causing Atrioventricular block second degree PEMBROLIZUMAB Demographics